Kubilay İNAN, Merve ŞENGÜL İNAN, İlknur AYTEKİN ÇELİK, Ozgur Omer YİLDİZ, Nurettin KARAOGLANOGLU

Akciğer Kanserinde Sağkalım ve Evre

Amaç: Akciğer kanseri, dünya çapında kanser ölümlerinin önde gelen nedenidir. Küçük hücreli dışı akciğer kanseri (KHDAK) için 5 yıllık sağkalım oranları %20 ile %70 arasında değişmektedir. Bu çalışmada KHDAK nedeniyle opere edilen toplam 83 hastada erken nüks oranları araştırılmakta ve literatürdeki veriler ışığın-da ilgili bulgular sunulmaktadır. Araçlar ve Yöntem: Mart 2019-Eylül 2021 tarihleri arasında malignite nedeniyle akciğer rezeksiyonu yapılan hastalar retrospek-tif olarak incelendi. Yaş, cinsiyet, ameliyat öncesi kemoterapi uygulamasının varlığı, yapılan ameliyatlar, ameliyat tarihleri, patoloji sonuçları, ameliyat sonrası evreleme, sağkalım ve nüksleri içeren hasta verileri belgelendi. Bulgular: Mart 2019 ile Eylül 2021 arasında malignite nedeniyle akciğer rezeksiyonu yapılan toplam 83 hasta incelendi. Has-taların medyan yaşı 62 idi. Toplam 4 hastada nüks gelişti ve 79'u nüks olmadan takiplerine devam etti. Akciğer rezeksiyonu yapılan hastaların sekizi (%9.6) postoperatif ilk 2 yıllık dönemde kaybedildi. Bu sekiz hastanın ortalama sağkalım süresi 14.6 ay (7-20 ay) idi. Sonuç: Yaş, cinsiyet, patolojik tip, tümörün yerleşim yeri gibi çeşitli parametreler incelenip karşılaştırılsa da cerrahi uygulanan hastaların uzun dönem sağkalımlarını etkileyen asıl parametrenin tümörün evresi olduğu bilinmektedir.

Anahtar Kelimeler:

Cerrahi, Göğüs Cerrahisi, Malignite, Kanser

Survival and Stage in Lung Cancer

Purpose: Lung cancer is the leading cause of cancer death worldwide. Although the 5-year survival rates of for non-small cell lung carcinoma (NSCLC) ranges from 20% to 70%. The present study investigates the rates of early recurrence in a total of 83 patients operated for NSCLC and presents the related findings in reference to the data available in the literature. Materials and Methods: Patients who underwent lung resection for malignancy between March 2019 and September 2021 were retrospectively examined. The patient data, including age, gender, presence of preoperative chemotherapy administration, opera-tions performed, operation dates, pathology results, postoperative staging, survival, and relapses, were documented. Results: A total of 83 patients who underwent lung resection for malignancy between March 2019 and September 2021 were examined. The patients had a median age of 62 years. Of the total number of patients four patients developed recurrence and 79 continued their follow-up without any recurrence. Of the patients who underwent lung resection, eight (9.6%) patients died within the first postoperative 2-year period. The mean survival period of these eight patients was 14.6 months (7–20 months). Conclusion: Although various parameters, such as age, gender, pathological type, and location of the tumor are examined and compared, according to the available data on the long-term survival of surgical patients, it is known that the only parameter that affects survival is the pathological stage of the patient.

Keywords:

Cancer, Malignancy, Surgery, Thoracic Surgery,

PDF

___

1. Allemani C, Weir HK, Carreira H. et al. CON-CORD Working Group. Global surveillance of cancer survival 1995-2009: analysis of individu-al data for 25.676.887 patients from 279 popula-tion-based registries in 67 countries (CONCORD-2). Lancet. 2015;385(9972):977-1010.
2. Martin J, Ginsberg RJ, Venkatraman ES. et al. Long-term results of combined-modality therapy in resectable non-small-cell lung cancer. J Clin Oncol. 2002;20(8):1989-1995.
3. Taylor MD, Nagji AS, Bhamidipati CM. et al. Tumor recurrence after complete resection for non-small cell lung cancer. Ann Thorac Surg. 2012;93(6):1813-1821.
4. Gourcerol D, Scherpereel A, Debeugny S. et al. Relevance of an extensive follow-up after sur-gery for nonsmall cell lung cancer. Eur Respir J. 2013;42(5):1357-1364.
5. Endo C, Sakurada A, Notsuda H. et al. Results of long-term follow-up of patients with completely resected non-small cell lung cancer. Ann Thorac Surg. 2012;93(4):1061-1068.
6. Westeel V, Choma D, Clément F. et al. Relevance of an intensive postoperative follow-up after sur-gery for non-small cell lung cancer. Ann Thorac Surg. 2000;70(4):1185-1190.
7. Yue D, Gong L, You J et al. Survival analysis of patients with non-small cell lung cancer who un-derwent surgical resection following 4 lung can-cer resection guidelines. BMC Cancer. 2014;14:422.
8. Schabath MB, Cote ML. Cancer progress and priorities: lung cancer. Cancer Epidemiol Bi-omarkers Prev. 2019;28(10):1563-1579.
9. Mehta HJ, Ross C, Silvestri GA. et al. Evaluation and treatment of high-risk patients with early-stage lung cancer. Clin Chest Med. 2011;32(4):783-797.
10. Vest MT, Herrin J, Soulos PR. et al. Use of new treatment modalities for non-small cell lung can-cer care in the Medicare population. Chest. 2013;143(2):429-435.
11. Scott WJ, Howington J, Feigenberg S. et al. Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinical prac-tice guidelines. 2nd ed. Chest. 2007;132(3):234-242.
12. Kratzke R, Franklin MJ. Lung cancer epidemiolo-gy. Schwab M, ed.: Encyclopedia of Cancer. Ber-lin, Germany: Springer; 2011:2100-2104.
13. Kocher F, Hilbe W, Seeber A. et al. Longitudinal analysis of 2293 NSCLC patients: a comprehen-sive study from the TYROL registry. Lung Can-cer. 2015;87(2):193-200.
14. Duma N, Santana-Davila R, Molina JR. Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment. Mayo Clin Proc. 2019;94(8):1623-1640.
15. Travis WD, Brambilla E, Burke AP. et al. Intro-duction to the 2015 World Health Organization classification of tumors of the lung, pleura, thy-mus, and heart. J Thorac Oncol. 2015;10(9):1240-1242.
16. Pardoll DM. The blockade of immune check-points in cancer immunotherapy. Nat Rev Can-cer. 2012;12(4): 252-264.
17. Gilligan D, Nicolson M, Smith I. et al. Preopera-tive chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22/NVALT 2/EORTC 08012 multicentre ran-domised trial and update of systematic review. Lancet. 2007;369(9577): 1929-1937.
18. Felip E, Rosell R, Maestre JA. et al. Spanish Lung Cancer Group. Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemother-apy versus surgery alone in early-stage non-small-cell lung cancer. J Clin Oncol. 2010;28(19):3138-3145.
19. Khullar OV, Liu Y, Gillespie T. et al. Survival After Sublobar Resection versus Lobectomy for Clinical Stage IA Lung Cancer: An Analysis from the National Cancer Data Base. J Thorac Oncol. 2015;10(11):1625-1633.
20. Billmeier SE, Ayanian JZ, Zaslavsky AM. et al. Predictors and outcomes of limited resection for early-stage non-small cell lung cancer. J Natl Cancer Inst. 2011;103(21):1621-1629.
21. Kodama K, Higashiyama M, Okami J. et al. On-cologic Outcomes of Segmentectomy Versus Lo-bectomy for Clinical T1a N0 M0 Non-Small Cell Lung Cancer. Ann Thorac Surg. 2016;101(2):504-511.
22. Kodama K, Doi O, Higashiyama M. et al. Inten-tional limited resection for selected patients with T1 N0 M0 non-small-cell lung cancer: a single-institution study. J Thorac Cardiovasc Surg. 1997;114(3):347-353.
23. İnan, K., İnan, M. Ş., Bıçakçıoğlu, P. et al. The surgical management in pneumonectomy cases for lung cancer treatment. Curr Thorac Surg. 2020;5(2):64-70.
24. Ferguson MK, Karrison T. Does pneumonecto-my for lung cancer adversely influence long-term survival? J Thorac Cardiovasc Surg. 2000;119(3):440-448.